Understanding how prenatal liver cells enter the brain through the blood-brain barrier
Investigating the role of the blood-brain barrier in trafficking prenatal liver-derived immune cells into the brain
This study is looking at how the blood-brain barrier develops in babies and how immune cells from the liver move into the brain, which is important for keeping the brain healthy as it grows.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10901479 on NIH RePORTER |
What this research studies
This research investigates the role of the blood-brain barrier (BBB) in the development of the brain and how immune cells from the prenatal liver migrate into the brain. Using innovative techniques, including in utero liver injections and single-cell RNA sequencing, the researchers aim to understand the cellular interactions that govern BBB formation and permeability during gestation. By studying these processes, the research seeks to uncover how the BBB regulates the entry of immune cells into the brain, which is crucial for brain health and development.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals under 21 years old, particularly those with conditions affecting brain development or immune system function.
Not a fit: Patients who are over 21 years old or do not have conditions related to brain development or immune system issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new insights into brain development and potential therapies for brain disorders related to BBB dysfunction.
How similar studies have performed: Other research has shown promising results in understanding the role of the blood-brain barrier in brain health, making this approach both relevant and potentially impactful.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Wedderburn-Pugh, Kaylee — University of California, San Francisco
- Study coordinator: Wedderburn-Pugh, Kaylee
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.